Abstract
PURPOSE: This study examined whether eating disorder (ED) psychopathology related to weight loss medication and over-the-counter weight loss supplement use over time in women. It was hypothesized that ED psychopathology at baseline would relate to the following 6-months later: (1) use of any weight loss medications or supplements; and specific use of: (2) over-the-counter weight loss supplements, (3) prescription weight loss medications, (4) glucagon-like peptide 1 (GLP-1) agonist medications used for weight loss. METHODS: Women in the United States were recruited for a 6-month long online study. Questionnaire data were provided, including the 7-item version of the Eating Disorder Examination Questionnaire. RESULTS: Baseline ED psychopathology was related to use of weight loss medications and supplements 6-months later, controlling for baseline use and body mass index (BMI). Analyses found greater odds of using over-the-counter weight loss supplements, prescription weight loss medications, and GLP-1 medications, at 6 months associated with higher baseline ED psychopathology, controlling for baseline weight loss medication/supplement use and BMI. CONCLUSION: Medications such as GLP-1s can benefit chronic disease management when used appropriately but these, and other weight loss medications and supplements, may also be appealing to those with ED psychopathology to promote restriction and weight loss. ED symptom screening is important prior to, and during, medication use. These data are relevant for prescribers and suggest that evaluation of ED symptoms, especially "atypical" anorexia nervosa presentations, may be warranted among those seeking weight loss medications. LEVEL OF EVIDENCE: Level IV: Evidence obtained from multiple time series with or without the intervention, such as case studies.